Cancer Immunotherapy Guidelines Committee

The Cancer Immunotherapy Guidelines Committee oversees the development of new disease-specific guidelines and updates for existing guidelines that provide guidance on the appropriate treatment algorithms and recommended administration of FDA-approved cancer immunotherapies as well as mitigating and managing adverse event.  The committee maintains standards for the SITC Cancer Immunotherapy Guidelines subcommittees to ensure the recommendations are unbiased, relevant and facilitate clinical decision-making leading to optimal patient care.

Chair

Madhav Dhodapkar, MD – Emory University